Digipath
Labs Earns ISO-17025 Accreditation under new 2017
Criteria
LAS
VEGAS,
NV
-- December
20, 2018
-- InvestorsHub NewsWire -- Digipath,
Inc. (OTCQB:
DIGP), a service-oriented
independent
testing
laboratory
and
data
firm
focused
on
the
developing
cannabis
and
hemp market,
is
pleased
to
announce
its
receipt of
ISO
17025:2017 accreditation
from
Perry
Johnson Laboratory Accreditation (PJLA) as Digipath's
accreditation
body.
In most
major
countries, ISO/IEC 17025 is
the standard of
accreditation in order to be deemed technically competent.
Laboratory accreditation uses criteria and procedures specifically
developed to determine technical competence, thus assuring
customers that the testing,
calibration
and
measurement data supplied by the laboratory or inspection service
are accurate and reliable.
The
International Organization
for
Standardization and International
Electrotechnical Commission(ISO/IEC)
specify
the general requirements for the competence to carry out tests
and/or calibrations, including sampling. ISO 17025:2017
covers testing and calibration performed using standard methods,
non-standard methods, and laboratory-developed methods as
applicable
to all organizations performing laboratory activities, regardless
of the number of personnel. The new 2017 standards provided for an
update to terminology, process approach, scope, and the concept of
risk-based thinking.
"Obtaining
accreditation
under the revised ISO-17025:2017
guidelines
was a team
effort by Digipath
Labs'
employees,
and is
a testament to our commitment
to best practices and reliability in testing,"
stated
Cindy Orser, PhD Digipath's Chief Science Officer and Laboratory
Director.
With
increased regulatory oversight of the cannabis industry on a
state
by state basis,
ISO-17025 accreditation is now a requirement and not an option.
"Digipath Labs has now brought its standard
of excellence
in cannabis testing under the updated ISO-17025:2017
umbrella
as we seek
to expand
our dominance in cannabis testing markets.
This is a
major step in positioning Digipath as a global leader in testing
services,"
added
Todd Denkin, CEO and Founder.
About Digipath, Inc. & Digipath Labs, Inc.
Digipath,
Inc. supports
the cannabis industry's best practices for reliable testing, data
acquisition, cannabis education and training, and brings unbiased
cannabis news coverage to the cannabis industry. Digipath
Labs provides
pharmaceutical-grade analysis and testing to the cannabis industry
to ensure producers, consumers, and patients know exactly what is
in the cannabis they ingest and to help maximize the quality of its
client's products through analysis, research, development, and
standardization.
Digipath Investor Relations & Financial Media
info@integrityir.com
Toll
Free: (888) 216-3595
www.IntegrityIR.com
Information
about
Forward-Looking
Statements
This
press
release
contains
"forward-looking
statements"
that
include
information
relating
to
future
events.
Forward-looking
statements
should
not
be
read
as
a
guarantee
of
future
performance
or
results
and
will
not
necessarily
be
accurate
indications
of
the
times
at,
or
by,
which
that
performance
or
those
results
will
be
achieved.
Forward-looking
statements
are
based
on
information
available
at
the
time
they
are
made
and/or
management's
good
faith
belief
as
of
that
time
with
respect
to
future
events
and
are
subject
to
risks
and
uncertainties
that
could
cause
actual
performance
or
results
to
differ
materially
from
those
expressed
in,
or
suggested
by,
the
forward-looking
statements.
Important
factors
that
could
cause
these
differences
include,
but
are
not
limited
to:
the
Company's
need
for
additional
funding,
the
demand
for
the
Company's
products,
governmental
regulation
of
the
cannabis
industry,
the
Company's
ability
to
maintain
customer
and
strategic
business
relationships,
the
impact
of
competitive
products
and
pricing,
growth
in
targeted
markets,
the
adequacy
of
the
Company's
liquidity
and
financial
strength
to
support
its
growth,
and
other
risks
that
may
be
detailed
from
time-to-time
in
the
Company's
filings
with
the
United
States
Securities
and
Exchange
Commission.
For
a
more
detailed
description
of
the
risk
factors
and
uncertainties
affecting
Digipath,
please
refer
to
the
Company's
recent
Securities
and
Exchange
Commission
filings,
which
are
available
at
www.sec.gov. The
Company
undertakes
no
obligation
to
publicly
update
or
revise
any
forward-looking
statements,
whether
as
a
result
of
new
information,
future
events,
or
otherwise.